Varex Imaging’s Quiet Quarter: Tariffs, Teledyne Ties, and a Non-GAAP Glow on the Way

Overview

Varex Imaging Corporation (Nasdaq: VREX) released its third‑quarter results for fiscal year 2026 amid a pending Teledyne Technologies Incorporated transaction and a decision to cancel the usual earnings conference call. The press release frames the quarter as a story of solid top‑line momentum aided by a tariff adjust­ment recovery, while keeping the guidance cart well away from the table. In classic corporate news‑release fashion, the core numbers are there to hold the line: revenues, margins, and per‑diluted‑share metrics, with a careful detour into non‑GAAP adjustments.

Financial Highlights at a Glance

Key figures show a company delivering modest year‑over‑year growth with a tilt toward non‑GAAP profitability. Highlights include:

• Revenue: $211 million for the quarter.
• Gross margin: GAAP 36%; Non‑GAAP 37% (up from 34% non‑GAAP in the prior year).
• Operating margin: GAAP 11%; Non‑GAAP 12%.
• Net income per diluted share: GAAP $0.37; Non‑GAAP $0.31.
• Cash flow from operations: $21 million.
• Product sales before IEEPA related adjustments: approximately $217 million.

On a segment basis, Medical revenue stood at $134 million and Industrial at $77 million, painting a picture of a diversified mix that helped cushion the top line. The company notes that non‑GAAP gross margin rose to 37% from 34% a year earlier, underscoring the impact of mix and accelerating gross profitability even as tariffs ebbed and flowed in the background.

Tariffs, Tariffs-Plus, and Guidance Gaps

The quarterly narrative leans into IEEPA tariff dynamics. Varex disclosed refunds totaling $17 million from U.S. Customs related to previously paid IEEPA tariffs, paired with a $7 million reduction to revenues to reflect an accrual for expected customer reimbursements of those tariffs. The net effect: roughly a $10 million uplift to third‑quarter gross profit. In other words, the tariff drumbeat didn’t break the rhythm; it punctuated it.

Management also notes a debt redemption and refinancing completed in March, shaping liquidity and leverage as the company navigates a period of strategic change tied to Teledyne’s transaction. And crucially, there is no financial guidance attached to the third‑quarter earnings release—the company cancelled its earnings call, a move that effectively freezes near‑term EPS consensus chatter until a formal update surfaces from the deal's settlement path.

Why This Matters for VREX and Its Peers

The numbers tell a familiar story for capital‑intensive imaging plays: solid demand in medical and industrial X‑ray components, a tilt toward higher‑margin non‑GAAP results, and the gravitational pull of tariffs and policy shifts. The Q3 results show:

• Resilience in a diversified portfolio—Medical remains a meaningful engine alongside Industrial, contributing to a steadier revenue mix even as end markets evolve.
• Gross margins benefiting from product mix and cost management, with non‑GAAP profitability stepping ahead of GAAP in a way that highlights the ongoing reconciliation between the two measures investors tend to watch.
• Liquidity and capital structure improvements that could be a tailwind or a trap depending on execution around the Teledyne deal and any subsequent regulatory approvals or strategic pivots.
• Tariff dynamics continuing to influence reported results but appear to be offset by refunds and revenue recognition adjustments, a reminder that the accounting treatment of geopolitical costs can materially affect the “EPS” story without changing the underlying operating cash generation.

With no fixed revenue forecast or forward EPS guidance disclosed, the market will be left to infer future trajectory from the non‑GAAP trend, the cash flow cadence, and the implied margin trajectory as the company adapts to the Teledyne transaction. For sector peers, the takeaway is twofold: maintain flexibility in cost and tariff management, and watch how non‑GAAP adjustments can mask or reveal underlying operating leverage in a period of transaction uncertainty.

About Varex

Varex Imaging Corporation is a designer and maker of X‑ray imaging components, including X‑ray tubes, digital detectors, and other imaging software and systems used across medical, industrial, and security applications. Headquartered in Salt Lake City, Utah, the company employs roughly 2,500 people globally. For more information visit www.vareximaging.com.

Forward‑Looking Statements

The release contains forward‑looking statements within the Private Securities Litigation Reform Act, including expectations about unaudited financial results, outlook, product demand, and management’s projections. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations. The absence of guidance for the near term means investors should be mindful of the ongoing regulatory and transaction‑related uncertainties surrounding Teledyne’s potential win for Varex, and should consider this as part of any EPS consensus assessment or revenue forecast exercise.

Conclusion: A Quarter of Strategic Breathing Room

VREX delivered a quarter that fits a cautious, if not optimistic, script: a stable top line, modestly expanding non‑GAAP profitability, and a cash-generating machine tempered by policy risk and a high‑stakes strategic move. The absence of explicit guidance should not be mistaken for weakness; rather, it’s a deliberate keepsake to the Teledyne deal’s timeline. For investors watching EPS, EPS consensus, and revenue forecasts, the quarter provides a breadcrumb trail rather than a marching path. If the company can translate this momentum into a clear post‑deal plan and a path to predictable non‑GAAP earnings, the stock could begin to reflect that predictability in the price of its equity and its peers’ adjustments in the broader X‑ray imaging ecosystem.